Obagi Medical Products, Inc. (Nasdaq:OMPI), a leader in topical aesthetic and therapeutic skin health systems, released the results of three new studies this weekend at the American Academy of Dermatology meeting in San Diego, CA. The studies explored the use of the Nu-Derm System with tretinoin, as prescribed by the investigators, in the treatment of melasma and hyperpigmentation in patients with Fitzpatrick skin types III – VI. Each study evaluated the efficacy and tolerability of the treatment on the skin as well as its effects on the patients’ emotional well-being.
“Nu-Derm with tretinoin has long been a go-to regimen, particularly in difficult-to-treat melasma, for many dermatologists,” Jim Hartman, Vice President Global Marketing and Business Development at Obagi, said. “Our objective in partnering with these respected experts in the field of dermatology for these studies was to provide clinical proof that Nu-Derm, in combination with varying percentages of tretinoin, based on recommendations from key opinion leaders, is a valid, effective option in many skin types, including darker skin patients, as well as in patients more sensitive to irritation. The results presented this weekend indicate that we successfully met that objective.”
The 75 patients in the three studies followed a morning regimen that included a foaming gel cleanser, toner, four percent hydroquinone product, exfoliation enhancer and a sunscreen with SPF 35. The evening regimen consisted of a foaming gel cleanser, toner and four percent hydroquinone product mixed with a tretinoin cream at various percentages. Patients reported high levels of patient satisfaction and improved quality of life metrics across the studies.
The studies postered and affiliated investigators are as follows:
Study 4581 - Treatment of Moderate or Marked Melasma in Darker Skin with a Four Percent Hydroquinone Skin Care System Plus 0.025% Tretinoin Cream:
Study 5131 - Treatment of Moderate or Marked Melasma with a Four Percent Hydroquinone Skin Care System Plus 0.1 Percent Tretinoin Cream: Comparison in Asian and Caucasian Patients:
- Lead investigator for Study 4581 is Pearl Grimes, MD (Los Angeles, CA)
Study 5139 - Treatment of Moderate or Marked Melasma in Darker Skin with a Four Percent Hydroquinone Skin Care System Plus 0.05% Tretinoin Cream:
- Lead investigator for Study 5131 is Dr. Suzanne Bruce (Suzanne Bruce & Associates, PA; Houston, TX)
- Lead investigators for Study 5139 are Michael Gold, MD (Nashville, TN), Marta Rendon, MD (Boca Raton, FL), Barry DiBernardo, MD (Monclair, NJ), Suzanne Bruce (Suzanne Bruce & Associates, PA; Houston, TX) and Chere Lucas-Anthony, MD (Boca Raton, FL)
The investigators reported considerable improvements in melasma and skin discoloration, in addition to high levels of patient satisfaction across all three studies.